Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

NULL
   
  • Closing Price Chg:
    -30.00p
  • 52 Week High: NULL
  • 52 Week Low: 1,424.00p
  • Currency: UK Pounds
  • Shares Issued: 66.04m
  • Volume: 0
  • RiskGrade: 128

Financial Analysis

Select chart: EPS | Dividend | Revenue

Latest Interim/Quarterly

Period Ending Period Revenue (£m) Pre-tax (£m) EPS Dividend
31-Dec-24 Interim 336.40 3.30 39.80p 10.30p

Key Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-20 551.40 46.30 77.30p 45.7 7.6 +6% 29.10p 0.8%
30-Jun-21 574.30 55.80 100.90p 49.2 1.6 +30% 32.00p 0.6%
30-Jun-22 593.40 48.40 82.70p 30.3 n/a -18% 32.00p 1.3%
30-Jun-23 689.70 39.40 84.80p 25.5 12.8 +2% 32.00p 1.5%
30-Jun-24 668.80 5.50 65.50p 25.2 n/a -23% 32.00p 1.9%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-25 671.96 76.77 76.72p 32.5 1.9 +17% 32.84p 0.0%
30-Jun-26 699.01 87.08 89.20p 28.0 1.7 +16% 34.66p 0.0%
30-Jun-27 731.77 95.26 102.38p 24.4 1.7 +15% 36.87p 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

Price / Earnings Data

5 Yr High 5 Yr Low 5 Yr Avg Curr / Avg
Latest 45.69 25.19 35.18 1.08

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

Genus Market Data

Currency UK Pounds
Share Price NULL
Closing Price Change -30.00p
% Change 0.00 %
52 Week High NULL
52 Week Low 1,424.00p
Volume 0
Shares Issued 66.04m
RiskGrade 128

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.41% below the market average92.41% below the market average92.41% below the market average92.41% below the market average92.41% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
68.43% above the market average68.43% above the market average68.43% above the market average68.43% above the market average68.43% above the market average
91.11% above the sector average91.11% above the sector average91.11% above the sector average91.11% above the sector average91.11% above the sector average
Income
98.32% below the market average98.32% below the market average98.32% below the market average98.32% below the market average98.32% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
91.96% below the market average91.96% below the market average91.96% below the market average91.96% below the market average91.96% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

What The Brokers Say

Strong Buy 6
Buy 2
Neutral 0
Sell 1
Strong Sell 0
Total 9
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Interim Final
Ex-Div 06-Mar-25 07-Nov-24
Paid 04-Apr-25 06-Dec-24
Amount 10.30p 21.70p

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

Genus Key Personnel

CEO Jorgen Kokke

Top of Page